In summary, based on tumor ER and/or PgR expression at diagnosis and (if available) baseline Ki67, postmenopausal patients with hormone receptor positive HER2-negative early breast cancer can be stratified for immediate surgery or neoadjuvant chemotherapy (Group 1) and others selected for NeoET (Group 3). Here, MKI67 is linked to breast carcinoma.